Remington's Pharmaceutical, Sciences

en al novello projektoration de la collectión de la colle

Eighteemth Edition



Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by Joseph P Remington Estate

Copyright 1948, 1951, by The Philadelphia College of Pharmacy and Science

Copyright © 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, by The Philadelphia College of Pharmacy and Science

All Rights Reserved

Library of Congress Catalog Card No. 60-53334 ISBN 0-912734-04-3

The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.

NOTICE—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.

Printed in the United States of America by the Mack Printing Company, Easton, Pennsylvania



Table of Contents

	Part 1 Orientation		44 45	Cholinomimetic Drugs	889
- 1	Scope	3			898
2	Evolution of Pharmacy	8	46		907
3	Ethics	20	47		916
4	The Practice of Community Pharmacy	28	48		929
5	Opportunities for Pharmacists in the Pharmaceuti-		49		943
•	cal Industry	33	50		948
6	Pharmacists in Government	38	51	*********	002
7	Drug Information	49			035
8	Research	60	52	== /	039
U	Research	00	53		
			54		048
	Part 2 Pharmaceutics		55		057
_			56	**************************************	072
9	Metrology and Calculation	69	57	,	082
10	Statistics	104	58		097
11	Computer Science	138	59		123
12	Calculus	145	60		132
13	Molecular Structure, Properties and States of		61		138
	Matter	158	62		163
14	Complex Formation	182	63		242
15	Thermodynamics	197	64	• • • • • • • • • • • • • • • • • • • •	249
16	Solutions and Phase Equilibria	207	65	5	272
17	lonic Solutions and Electrolytic Equilibria	228	66	Pharmaceutical Necessities	286
18	Reaction Kinetics	247	67	Adverse Drug Reactions	330
19	Disperse Systems	257	68	Pharmacogenetics 18	344
20	Rheology	310	69	Pharmacological Aspects of Drug Abuse 13	349
			70	Introduction of New Drugs	365
	Part 3 Pharmaceutical Chemistry				
				Part 7 Diological Products	
21	Inorganic Pharmaceutical Chemistry	329		•.	
22	Organic Pharmaceutical Chemistry	356	71	· · · · · · · · · · · · · · · · · · ·	379
23	Natural Products	380	72	Immunizing Agents and Diagnostic Skin	
24	Drug Nomenclature—United States Adopted				389
	Names	412	73		405
25	Structure-Activity Relationship and Drug		74	Biotechnology and Drugs 14	416
	Design	422			
				Part 8 Pharmaceutical Preparations and Their	
	Part 4 Testing and Analysis			Manufacture	
26	Analysis of Medicinals	435	75	Preformulation 1	435
27	Biological Testing	484	76		451
28	Clinical Analysis	495	77		459
29	Chromatography	529	78		470
30	Instrumental Methods of Analysis	555			470 481
31	· · · · · · · · · · · · · · · · · · ·	589	79		-
01	Dissolution	309	80		499
	· ·		01	•	504
Po	rt 5 Radioisotopes in Pharmacy and Medic	ine	82		513
^~	M. I I. do let de la		83	Solutions, Emulsions, Suspensions and	E 40
32	Fundamentals of Radioisotopes	605			519
33	Medical Applications of Radioisotopes	624	84		545
			85		570
	Part 6 Pharmaceutical and Medicinal Agent	ts	86	•	581
			87		596
34	Diseases: Manifestations and Patho-		88		615
	physiology	655	89	•	633
35	Drug Absorption, Action and Disposition	697	90		666
36	Basic Pharmacokinetics	725	91		676
37	Clinical Pharmacokinetics	746	92	Aerosols 10	694
38	Topical Drugs	757			
39	Gastrointestinal Drugs	774		Part 9 Pharmaceutical Practice	
40	Blood, Fluids, Electrolytes and Hematologic			Pail & Phaimateolitai Platinte	
	Drugs	800	93	Ambulatory Patient Care	715
41	Cardiovascular Drugs	831	94		737
42	Respiratory Drugs	860	95		758
	Sympothomimetic Drugs	870			773



97	The Patient: Behavioral Determinants	1788	106	Poison Control	190
98	Patient Communication	1796	107	Laws Governing Pharmacy	1914
99	Drug Education	1803	108	Community Pharmacy Economics and	
100	Patient Compliance	1813		Management	1940
101	The Prescription	1828	109	Dental Services	1957
102	Drug Interactions	1842			
103	Clinical Drug Literature	1859		Index	
104	Health Accessories	1864			
105	Surgical Supplies	1805		Alphohetic Index	106



Preformulation

Louis J Ravin, PhD

Department of Pharmaceutics Research & Development Smith Kline & French Laboratories King of Prussia, PA 19406

Galen W Radebaugh, PhD

Director of Pharmaceutics Parke-Davis Pharmaceutical Research Division Warner-Lambert Co Morris Plains, NJ 07950

The attention presently being given to multisource pharmaceutical products regarding their equivalency places much emphasis on the formulation of these products. In some instances, the bioavailability of a drug formulation represents a quality parameter of enormous proportion. It is a matter of record that with certain drugs, depending on the formulation, the rate at which the drug substance becomes available can vary significantly from very high to none at all. As a result, the effectiveness of these formulations will range dramatically from that expected to no effect. Unfortunately, most examples are less dramatic and fall somewhere in between. The difference in the bioavailability of these drug products is less readily discernible, but nonetheless real. This has led to a great deal of confusion and information which, though understood by the scientist, is unclear and jumbled to the practitioner. That information which is available also has been interpreted differently by different individuals or groups, depending very often on the motivation, viewpoint and attitude of the interpreter.

Drug products indeed do vary in their bioavailability characteristics and this variation, in most instances, is related directly to formulation considerations. To optimize the performance of drug products, it is necessary to have a complete understanding of the physical-chemical properties of drug substances prior to formulating them into drug products. The development of an optimum formulation is not an easy task, and many factors readily influence formulation properties. Drug substances rarely are administered as chemical entities, but almost always are given in some kind of formulation. These may vary from a simple solution to a very complex drug delivery system. The complexity usually is not intentional, but rather is determined by the properties that are expected from or built into the dosage form and by the resulting composition that is required to achieve these qualities.

The high degree of uniformity, physiological availability and therapeutic quality expected of modern medicinal products usually are the results of considerable effort and expertise on the part of the formulating pharmacist. These qualities are attained by careful selection and control of the quality of the various ingredients employed, appropriate manufacturing according to well-defined processes and, most importantly, adequate consideration of the many variables that may influence the composition, stability and utility of the product. In dealing with the formulation of new products it has become necessary to apply the best research methods and tools in order to develop, produce and control the potent, stable and effective dosage forms which make up our modern medical armamentarium.

The pharmaceutical formulator has need for specialized

areas of science in order to acquire scientific information about the drug substance which is necessary to develop an optimum dosage form. The pharmaceutical industry is in an era in which one can no longer rely on past experience to formulate. A thorough understanding of the physical and chemical properties as well as the pharmacokinetic and biopharmaceutical behavior of each drug substance being developed is necessary. In short, as much information as possible must be acquired about the drug substance very early in its development. This requires an interdisciplinary approach at the preformulation stage of development. Fig 75-1 schematically indicates that the development of any drug product requires a multidisciplinary approach, involving basic science, during the preformulation stage followed by applied science during the development stage.

This chapter will discuss the physical-chemical evaluation that takes place during the preformulation stage of development. In addition, consideration will be given to some specialized formulation ingredients that may require discretion in their selection.

Preformulation may be described as a stage of development during which the physical pharmacist characterizes the physical-chemical properties of the drug substance in question which are considered important in the formulation of a stable, effective and safe dosage form. Such parameters as crystal size and shape, pH-solubility profile, pH-stability profile, polymorphism, partitioning effect, drug permeability and dissolution behavior are evaluated. During this evaluation possible interactions with various inert ingredients intended for use in the final dosage form also are considered. The data obtained from this evaluation are integrated with data obtained from the preliminary pharmacologic and biochemical studies and provide the formulating pharmacist with information that permits selection of the optimum dosage form containing the most desirable inert ingredients for use in its development.




Fig 75-1. The wheels of product development.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

